Journal article
Elevated levels of BRAFV600 mutant circulating tumor DNA and circulating hepatocyte growth factor are associated with poor prognosis in patients with metastatic melanoma
W Lu, L Burton, J Larkin, PB Chapman, PA Ascierto, A Ribas, C Robert, JA Sosman, GA McArthur, I Chang, I Caro, E Penuel, Y Yan, MJ Wongchenko
JCO Precision Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2018
DOI: 10.1200/PO.17.00168
Abstract
Purpose We performed a retrospective exploratory analysis to evaluate the prognostic and predictive effect of two circulating biomarkers, BRAFV600 mutant circulating tumor DNA (ctDNA) and circulating hepatocyte growth factor (cHGF), in metastatic melanoma. Materials and Methods This study evaluated patients from BRIM-3, a phase III trial comparing vemurafenib and dacarbazine in 675 patients with BRAFV600 mutated advanced melanoma. ctDNA was measured using droplet digital polymerase chain reaction, and cHGF was measured by enzyme-linked immunosorbent assay. Overall survival (OS) was estimated using the Kaplan-Meier method, and hazard ratios (HRs) were estimated using Cox proportional hazards ..
View full abstract